Compare CLBT & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLBT | IRON |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | Israel | United States |
| Employees | 1285 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.9B |
| IPO Year | N/A | 2020 |
| Metric | CLBT | IRON |
|---|---|---|
| Price | $14.54 | $75.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $22.50 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 1.5M | 441.7K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.45 | N/A |
| Revenue Next Year | $17.47 | $283.52 |
| P/E Ratio | $45.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.03 | $40.00 |
| 52 Week High | $19.98 | $99.50 |
| Indicator | CLBT | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 51.85 |
| Support Level | $12.53 | $70.29 |
| Resistance Level | $15.15 | $82.65 |
| Average True Range (ATR) | 0.64 | 3.33 |
| MACD | -0.15 | -0.16 |
| Stochastic Oscillator | 24.49 | 49.48 |
Cellebrite DI Ltd provides AI-powered digital investigative and intelligence solutions that help public and private sector customers transform investigative workflows, make digital data more accessible and actionable, and improve the efficiency of mobile research and application security. Its solutions support law enforcement, defense, and intelligence agencies in advancing investigations, border security, counterterrorism, intelligence operations, and cyber operations. The company's software also enables enterprises and service providers to collect and review data for corporate investigations, eDiscovery, incident response, and mobile application validation. It operates in the Americas, APAC, and EMEA, with the majority of revenue from the Americas.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.